Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study (BASIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04016324
Recruitment Status : Recruiting
First Posted : July 11, 2019
Last Update Posted : July 7, 2020
Sponsor:
Information provided by (Responsible Party):
MedtronicNeuro

Brief Summary:
Post-market clinical follow-up for continued assessment of safety and performance of the InterStim basic evaluation lead and foramen needle(s) used during a therapy evaluation.

Condition or disease Intervention/treatment Phase
Overactive Bladder Urinary Urge Incontinence Urgency-frequency Syndrome Device: InterStim Basic Evaluation lead and foramen needle Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: To characterize proportion of subjects who demonstrate motor or sensory response(s) during lead placement using the InterStim Basic Evaluation Lead.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: InterStim Basic Evaluation Lead Post Market Clinical Follow-Up Study
Actual Study Start Date : November 28, 2019
Estimated Primary Completion Date : August 1, 2020
Estimated Study Completion Date : August 1, 2020

Arm Intervention/treatment
Basic evaluation
Subjects with overactive bladder will go through InterStim basic evaluation with the commercially approved foramen needle and basic evaluation kit.
Device: InterStim Basic Evaluation lead and foramen needle
Commercial devices within their intended use as described in approved Instructions for Use.




Primary Outcome Measures :
  1. Motor or sensory response(s) during lead placement [ Time Frame: During lead implant ]
    To characterize the proportion of subjects who demonstrate motor or sensory response(s) during lead placement using the InterStim basic evaluation lead.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects 18 years of age or older
  2. Candidate for sacral neuromodulation in accordance with the InterStim System labeling
  3. Have a diagnosis of overactive bladder (OAB) as demonstrated by either urinary urge incontinence and/or urinary frequency on a 3-day voiding diary
  4. Willing and able to accurately complete study diaries, questionnaire, attend visits, and comply with the study protocol
  5. Willing and able to provide signed and dated informed consent

Exclusion Criteria:

  1. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
  2. Have implantable pacemakers, or defibrillators
  3. Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component
  4. Have knowledge of planned MRIs, diathermy, microwave exposure, high output ultrasonic exposure, or radio frequency (RF) energy exposure not included within the scanning conditions provided with the InterStim System labeling
  5. Women who are pregnant or planning to become pregnant during participation in the study
  6. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements
  7. Concurrent participation in another clinical study that may add additional safety risks and/or confound study results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04016324


Contacts
Layout table for location contacts
Contact: Rachael McNamara 763.526.8107 rachael.m.mcnamara@medtronic.com

Locations
Show Show 17 study locations
Sponsors and Collaborators
MedtronicNeuro
Investigators
Layout table for investigator information
Study Director: BASIC Clinical Research Study Team Medtronic
Layout table for additonal information
Responsible Party: MedtronicNeuro
ClinicalTrials.gov Identifier: NCT04016324    
Other Study ID Numbers: MDT19002
First Posted: July 11, 2019    Key Record Dates
Last Update Posted: July 7, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by MedtronicNeuro:
Overactive Bladder
Urinary Urge Incontinence
Urgency-frequency Syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder, Overactive
Urinary Incontinence, Urge
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Urinary Incontinence
Urination Disorders